Duchenne Muscular Dystrophy (Duchenne)
A Phase 2 Trial of EDG-5506 in Children with Duchenne
Children with Duchenne aged 4 to 9 years on stable corticosteroids
Lynx is a placebo-controlled trial to assess the effect of three doses of EDG-5506 over 12 weeks on safety, pharmacokinetics (PK) and biomarkers of muscle damage. After the initial 12 weeks, LYNX participants will then continue on open-label EDG-5506 for an additional 9 months to gain further insights into safety and functional measures.
Becker Muscular Dystrophy (Becker)
A Pivotal Cohort within CANYON of EDG-5506 in Adults with Becker
Adults with Becker aged 18 to 50 years
GRAND CANYON is a global, placebo-controlled study to assess the effect of EDG-5506 over an 18-month period on safety and efficacy, with North Star Ambulatory Assessment (NSAA) as the primary endpoint.
A Phase 2 Trial of EDG-5506 in Individuals with Becker
Active, Not Recruiting
Individuals with Becker aged 12 to 50 years
CANYON is a placebo-controlled trial to assess the effect of EDG-5506 over a 12-month period on safety, PK, biomarkers such as creatine kinase (CK) and functional measures.
A Study of EDG-5506 in Adult Males With Becker
Active, Not Recruiting
Adults with Becker aged 18 to 55 years old
ARCH is an open-label trial to assess the effect of escalating doses of EDG-5506 over 2 years on safety, PK, biomarkers of muscle damage such as CK and fast skeletal muscle troponin I, measures of function with North Star Ambulatory Assessment (NSAA) and North Star Assessment for Limb Girdle Type Muscular Dystrophies (NSAD), time function tests and patient-reported outcomes.
Phase 1 Trial of EDG-7500
A Phase 1 trial designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of EDG-7500 in healthy adults.
Developing new therapies for people with muscle disorders.
Edgewise is committed to developing new therapies for people living with severe, genetic neuromuscular or cardiac disorders. Novel therapies require years of laboratory research and clinical testing to evaluate safety and efficacy. Volunteers who enroll in clinical trials help Edgewise evaluate the potential benefits and safety profile of these investigational therapies in humans. Additionally, investigational therapies must successfully progress through various phases of clinical research before they can be approved for use in the clinical setting.
Please click the orange buttons to learn more about our active clinical trials and see if you qualify to participate. By taking part in one of our clinical trials, you can help us make a difference for the entire community of people living with severe, genetic neuromuscular or cardiac disorders.